QURE - uniQure N.V.
IEX Last Trade
5.85
-0.370 -6.325%
Share volume: 439,477
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.22
-0.37
-5.95%
Fundamental analysis
18%
Profitability
2%
Dept financing
18%
Liquidity
75%
Performance
20%
Performance
5 Days
-5.49%
1 Month
-23.33%
3 Months
25.00%
6 Months
-12.56%
1 Year
-32.99%
2 Year
-69.70%
Key data
Stock price
$5.85
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.73 - $11.35
52 WEEK CHANGE
-$0.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO:
Region: US
Website: uniqure.com
Employees: 588
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: uniqure.com
Employees: 588
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
Recent news